BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37316578)

  • 21. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
    Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
    Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
    Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
    Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
    Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
    Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer.
    Ganju RG; TenNapel M; Spoozak L; Chen AM; Hoover A
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):104-112. PubMed ID: 31397078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
    Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer.
    Huang CY; Sun FJ; Lee J
    Nutrition; 2020 Apr; 72():110642. PubMed ID: 31986319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application.
    Sivapalan L; Kocher HM; Ross-Adams H; Chelala C
    Pancreatology; 2021 Mar; 21(2):363-378. PubMed ID: 33451936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
    Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trunk muscle quality and quantity predict the development of metabolic syndrome and the increase in the number of its components in individuals without metabolic syndrome.
    Tanaka M; Okada H; Hashimoto Y; Kumagai M; Nishimura H; Fukui M
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1161-1168. PubMed ID: 32448718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computed tomography-based body composition is associated with adverse clinical outcomes among older patients with sepsis in the emergency department.
    Li Q; Shang N; Gao Q; Yang L; Guo S
    Eur Geriatr Med; 2023 Apr; 14(2):353-361. PubMed ID: 36780105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma.
    Riner AN; Herremans KM; Vudatha V; Han S; Qu X; Liu J; Mukhopadhyay N; Freudenberger DC; George TJ; Judge SM; Judge AR; Hughes SJ; Trevino JG
    J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):149-158. PubMed ID: 38123146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review.
    McGovern J; Dolan RD; Horgan PG; Laird BJ; McMillan DC
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):1408-1417. PubMed ID: 34664431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation.
    Bardoscia L; Besutti G; Pellegrini M; Pagano M; Bonelli C; Bonelli E; Braglia L; Cozzi S; Roncali M; Iotti C; Pinto C; Pattacini P; Ciammella P
    Front Nutr; 2022; 9():994499. PubMed ID: 36466387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with variability in skeletal muscle radiodensity in patients with metastatic cancer.
    Calixto-Lima L; Wiegert EVM; de Oliveira LC; Chaves GV; Avesani CM; Bezerra FF
    Nutrition; 2024 Apr; 120():112351. PubMed ID: 38330891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.